Virios Therapeutics, Inc.
News
VIRI Stock Earnings: Virios Therapeutics Beats EPS for Q2 2024
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nVIRI stock results show that Virios Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.\nThe post VIRI...\n more…
Virios Therapeutics Announces Second Quarter 2024 Financial Results
Globe Newswire - Bateman Horne Center completed enrollment in its groundbreaking investigator-initiated Long-COVID phase 2a study featuring valacyclovir and celecoxib (IMC-2) - - Top-line results from the...\n more…
Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
Globe Newswire ATLANTA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the Company ), a development-stage biotechnology company focused on advancing novel antiviral therapies to...\n more…
Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center
Globe Newswire - Virios projects releasing top line results from this groundbreaking Proof of Concept study in October 2024 - - Published data indicates increased Epstein-Barr herpes virus in Long-COVID patients...\n more…
Virios Therapeutics (NASDAQ:VIRI) Receives New Coverage from Analysts at Maxim Group
Ticker Report Investment analysts at Maxim Group initiated coverage on shares of Virios Therapeutics (NASDAQ:VIRI - Get Free Report) in a research report issued on Thursday, Benzinga reports. The firm set a "buy...\n more…